Evidence map›Paper›PMID 30535489›Full record

ArticleMolecular medicine reports2019

MicroRNA‑363‑3p inhibits hepatocarcinogenesis by targeting HMGA2 and is associated with liver cancer stage.

Jing Wang, Huimin Liang, Haize Ge, Xinling Guo, Dongmei Gu, Yuhua Yuan

Open access · hybridAbstract read
In one paragraph

Article in Molecular medicine reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Role of microRNA-363 during tumor progression and invasion.Journal of physiology and biochemistry · 2024
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Jing Wang *Department of Clinical Laboratory, Tianjin Medical University General Hospital Airport Site, Tianjin 300308, P.R. China.
Huimin Liang *School of Nursing, Tianjin Medical University, Tianjin 300070, P.R. China.
Haize GeDepartment of Clinical Laboratory, The Third Central Hospital of Tianjin, Tianjin 300170, P.R. China.
Xinling GuoDepartment of Clinical Laboratory, Tianjin Medical University General Hospital Airport Site, Tianjin 300308, P.R. China.
Dongmei GuDepartment of Clinical Laboratory, Tianjin Medical University General Hospital Airport Site, Tianjin 300308, P.R. China.
Yuhua YuanDepartment of Clinical Laboratory, Tianjin Medical University General Hospital Airport Site, Tianjin 300308, P.R. China.
Tianjin Medical University General Hospital · CNTianjin Medical University · CNTianjin Third Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The importance of microRNAs (miRNAs) in cancer development has been widely recognized in recent decades. In the present study, the function and mechanism of miRNA‑363‑3p (miR‑363‑3p), formerly characterized as a tumor suppressor, in the hepatocarcinogenesis of liver cancer cells was investigated. Reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) was applied to detect the expression of miR‑363‑3p in liver cancer tissues. Cell proliferation, survival and migration capacities were determined by MTT, colony formation and wound‑healing assays, respectively. The targeting of high mobility group AT‑hook 2 (HMGA2) mRNA by miR‑363‑3p was confirmed by bioinformatics analysis, and RT‑qPCR, luciferase reporter and western blot assays. The correlation between the expression levels of HMGA2 and miR‑363‑3p was analyzed. The RT‑qPCR results revealed that the levels of miR‑363‑3p were downregulated in liver cancer tissues. Cellular assays validated that miR‑363‑3p exerted tumor suppressing functions, including the inhibition of cell proliferation, survival and migration abilities in two liver cancer cell lines. Bioinformatics prediction and subsequent experiments demonstrated that HMGA2 was a direct target of miR‑363‑3p. Restoration of the expression of HMGA2 in miR‑363‑3p mimic‑transfected cells reversed the tumor suppressing effects caused by miR‑363‑3p. Finally, there was a significant negative correlation between the expression levels of HMGA2 and miR‑363‑3p in liver cancer tissues. miR‑363‑3p was identified as an important tumor suppressor in liver cancer via targeting HMGA2, which may have potential benefits in liver cancer therapy.

Indexed as

CarcinogenesisCarcinoma, HepatocellularCell Line, TumorCell MovementCell ProliferationDown-RegulationGene Expression Regulation, NeoplasticGenes, Tumor SuppressorHep G2 CellsHMGA2 ProteinHumansLiverLiver NeoplasmsMicroRNAsNeoplasm StagingHMGA2 ProteinHMGA2 protein, humanMicroRNAsMIRN363 microRNA, humanhepatocarcinogenesishigh mobility group AT-hook 2liver cancermicroRNA-363-3ptumor suppressor

Identifiers

PMID30535489
PMCPMC6323225
OpenAlexW2902258834

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.